Abstract
Heart failure (HF) is the culmination of all preceding cardiovascular events and the successes and failures of attempted and administered interventions. It is the cumulative effects of all abnormalities in the heart, which culminate in the functional impairment of the cardiac pump. Once the patient reaches the stage of symptomatic HF, the prognosis becomes poor. The more severe the HF, the nearer the patient is to death, and therefore the less room for mistakes in managing these patients. For these reasons, attention to details such as accuracy of diagnoses, correct assessments of severity, profound understanding of the pathophysiological processes and institution of timely therapy are crucial, and it calls for no less than the most skilled of HF specialists if the patients were to stand any chance of successfully fighting against this lethal condition. This chapter intends to lay the foundations for rational approaches to therapy.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Task Force for Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of European Society of Cardiology; Dickstein K, Cohen-Solal A, Filippatos G, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur Heart J. 2008;29(19):2388-2442.
Cotter G, Williams SG, Vered Z, Tan LB. Role of cardiac power in heart failure. Curr Opin Cardiol. 2003;18:215-222.
Kannel WB, Belanger AJ. Epidemiology of heart failure. Am Heart J. 1991;121(3 pt 1):951-957.
http://www.heartstats.org. Accessed 21 Jan 2009.
Cowie MR, Wood DA, Coats AJS, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20:421-428.
Stewart S, Jenkins A, Buchan S, McGuire A, Capewell S, McMurray JJ. The current cost of heart failure to the National Health Service in the UK. Eur J Heart Fail. 2002;4(3):361-371.
Cowie MR, Wood DA, Coats AJ, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J. 1999;20(6):421-428.
Bart BA, Shaw LK, McCants CB Jr, et al. Clinical determinants of mortality in patients with angiographically diagnosed ischemic or nonischemic cardiomyopathy. J Am Coll Cardiol. 1997;30:1002-1008.
Williams SG, Tzeng B-H, Tan LB. Cardiogenic shock: physiological and biochemical concepts. In: David Hasdai, Peter B Berger, Alexander Battler, David R Holmes Jr, eds. Cardiogenic Shock: Diagnosis and Treatment. New Jersey: Humana; 2002:7-32.
Williams SG, Wright DJ, Tan LB. Management of cardiogenic shock complicating acute myocardial infarction: towards evidence based medical practice. Heart. 2000;83:621-626.
Kannel WB, Castelli WP, McNamara PM, McKee PA, Feinleib M. of blood pressure in the development of congestive heart failure. The Framingham study. N Engl J Med. 1972;287:781-787.
Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med. 1990;322:1561-1566.
Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med. 2000;342(15):1077-1084.
Williams SG, Barker D, Goldspink DF, Tan LB. A reappraisal of concepts in heart failure: Central role of cardiac power reserve. Arch Med Sci. 2005;1:65-74.
Harris P. Evolution and the cardiac patient. Cardiovasc Res. 1983;17(7):437-445.
Lang CC, Mancini DM. Non-cardiac comorbidities in chronic heart failure. Heart. 2007;93:665-671.
Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc. 1997;45:968-974.
Wei JY. Age and the cardiovascular system. N Engl J Med. 1992;327:1735-1739.
Lakatta EG. Cardiovascular regulatory mechanisms in advanced age. Physiol Rev. 1993;73:413-467.
Olivetti G, Melissari M, Capasso JM, Anversa P. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ Res. 1991;68:1560-1568.
Fleg JL, O’Connor F, Gerstenblith G, et al. Impact of age on the cardiovascular response to dynamic upright exercise in healthy men and women. J Appl Physiol. 1995;78:890-900.
Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among Medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226-1233.
Tan LB, Murphy R. Shifts in mortality curves: saving or extending lives? Lancet. 1999;354:1378-1381.
Rich MW. Heart failure in the oldest patients: the impact of comorbid conditions. Am J Geriatr Cardiol. 2005;14:134-141.
Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol. 2002;39:1780-1786.
Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035-2038.
Rodrigues B, McNeill JH. The diabetic heart: metabolic causes for the development of a cardiomyopathy. Cardiovasc Res. 1992;26:913-922.
Williams SG, Ng LL, O’Brien R, Taylor S, Wright DJ, Tan LB. Is plasma N-BNP a good indicator of the functional reserve of failing hearts? The FRESH-BNP study. Eur J Heart Fail. 2004;6(7):891-900.
Latini R, Masson S, Wong M, et al. for the Val-HeFT Investigators. Incremental prognostic value of changes in B-type natriuretic peptide in heart failure with depressed ejection fraction. Am J Med. 2006;119:70.e23-70.e30.
Urban P, Stauffer JC, Bleed D, et al. A randomized evaluation of early revascularization to treat shock complicating acute myocardial infarction. The (Swiss) Multicenter Trial of Angioplasty for Shock-(S)MASH. Eur Heart J. 1999;20:1030-1038.
Fincke R, Hochman JS, Lowe AM, et al.; SHOCK Investigators. Cardiac power is the strongest hemodynamic correlate of mortality in cardiogenic shock: a report from the SHOCK trial registry. J Am Coll Cardiol. 2004;44(2):340-348.
Braunstein JB, Anderson GF, Gerstenblith G, et al. Noncardiac comorbidity increases preventable hospitalizations and mortality among medicare beneficiaries with chronic heart failure. J Am Coll Cardiol. 2003;42:1226-1233.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2010 Springer London
About this chapter
Cite this chapter
Tan, LB., Lewis, N., Barker, D. (2010). Definition, Diagnosis, Epidemiology, Etiology and Pathophysiology of Heart Failure. In: Henein, M. (eds) Heart Failure in Clinical Practice. Springer, London. https://doi.org/10.1007/978-1-84996-153-0_1
Download citation
DOI: https://doi.org/10.1007/978-1-84996-153-0_1
Published:
Publisher Name: Springer, London
Print ISBN: 978-1-84996-152-3
Online ISBN: 978-1-84996-153-0
eBook Packages: MedicineMedicine (R0)